Biogen Inc. (BIIB)
Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / July 16, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Invites Shareholders In Biogen Inc Who Incurred Losses To Initiate Dialogue Please Be Aware Of The Deadline In This Matter
LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before July 22, 2024.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Inc. Lawsuit - BIIB
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Biogen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2024 - BIIB
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Shareholders that lost money on Biogen Inc.(BIIB) should contact Levi & Korsinsky about pending Class Action - BIIB
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ:BIIB) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Biogen Inc. securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period").
Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ:BIIB) and certain officers. The class action, filed in the United States District Court for the District of Colorado, and docketed under 24-cv-01444, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biogen securities between February 3, 2022 and February 13, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
IMMINENT BIIB DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Biogen Inc. Investors to Join the Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ:BIIB) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Biogen Inc. securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period").
